Search for: "Anda Pharmaceuticals, Inc" Results 41 - 60 of 604
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
31 Mar 2015, 9:59 pm by Patent Docs
The case involved patentee Senju Pharmaceutical's (joined by Kyorin Pharmaceutical Co. and Allergan, Inc.) suit against Lupin Ltd., Lupin Pharmaceuticals, and Hi-Tech Pharmacal in response to a Paragraph IV certification against Senju's patented ocular antimicrobial agent containing the drug gatifloxacin as claimed in re-examined U.S. [read post]
20 Feb 2013, 7:37 am by Docket Navigator
Teva Pharmaceuticals USA Inc., et. al., 1-10-cv-00805 (DED February 11, 2013, Order) (Burke, M.J.). [read post]
10 Nov 2020, 8:53 pm by Patent Docs
Brands LLC of prior Federal Circuit interpretations that venue was coincident with personal jurisdiction, last Thursday the Federal Circuit arrived at a decision regarding where proper venue does not lie in ANDA litigation, in Valeant Pharmaceuticals North America LLC v. [read post]
14 Feb 2013, 9:59 pm by Patent Docs
Indeed, the current squabble over "reverse payment" settlement agreements of lawsuits under the ANDA provisions of the Hatch-Waxman Act (codified at 35 U.S.C. [read post]
14 Feb 2017, 9:13 pm by Patent Docs
The lawsuit involved Watson's ANDA filing seeking approval for a generic version of Shire's controlled-release oral pharmaceutical composition for the treatment of inflammatory bowel disease, Crohn's disease, and ulcerative colitis, sold by Shire under the brand name LIALDA®. [read post]
19 Oct 2010, 7:31 am by Phil
The following is excerpted from an October 18, 2010 Somaxon press release published at Business Wire: Somaxon Pharmaceuticals, Inc. [read post]
1 Sep 2015, 9:59 pm by Patent Docs
Patent No. 7,772,209, owned by Lilly, would be infringed by the ANDA products for which Defendants Teva Parenteral Medicines, Inc.; Teva Pharmaceuticals USA, Inc.; APP Pharmaceuticals, LLC; Barr Laboratories, Inc.; and Pliva Hrvatska D.O.O. sought approval to market (opinion).... [read post]
11 Sep 2012, 5:30 am by Gene Quinn
Par Pharmaceutical, Inc., which dealt with whether a drug covered by an Abbreviated New Drug Application (ANDA) infringed the patents owned by that patent owner relative to the proton pump inhibitors (PPI) product omeprazole. [read post]
20 Aug 2020, 9:59 pm by Patent Docs
Noonan -- ANDA litigation, pursuant to the Hatch-Waxman Act, has become more complicated over the years since enactment of the statute in 1984, with more patents being asserted and more parties participating over the opportunity to market a generic version of a branded, innovator drug. [read post]
18 Aug 2022, 11:39 am by Eileen McDermott
’s abbreviated new drug application (ANDA) does not infringe two patents owned by Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (collectively, Par). [read post]
18 Aug 2022, 11:39 am by Eileen McDermott
’s abbreviated new drug application (ANDA) does not infringe two patents owned by Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (collectively, Par). [read post]
9 Aug 2012, 9:59 pm by Patent Docs
The case involved a District Court grant of a preliminary injunction to Momenta in litigation between two ANDA filers. [read post]
7 Aug 2018, 8:20 am by RT
ANI Pharmaceuticals, Inc., 2018 WL 3677923, No. 17-4910 (D. [read post]
5 Dec 2008, 5:31 am
By Mark Chael -- On December 2nd, Mylan, Inc. and Mylan Pharmaceuticals, Inc. announced that they had settled their dispute with Novartis Pharmaceuticals Corp., Novartis Corp., and Novartis International AG over a generic version of Novartis' Femara ® tablets.According to the press release, Femara ® tablets, which are used in the treatment of breast cancer, had U.S. sales of about $470 million for the 12 months ending September 30, 2008.… [read post]
14 Jan 2020, 9:10 pm by Patent Docs
The issue arose in ANDA litigation, where the District Court found claim 6 of U.S. [read post]